


**THE ADHERENCE TO MEDICAL
THERAPY AFTER LOWER
EXTREMITIES ARTERY
DISEASE REVASCLARIZATION**

CENTRO CONGRESSI UNIVERSITÀ FEDERICO II - VIA PARTENOPE 36

Napoli
25 novembre
2021




Il ruolo dell'aderenza terapeutica nelle malattie Cardiovascolari

Prof. Paolo Calabrò

Università della Campania «Luigi Vanvitelli»

AORN Sant'Anna e San Sebastiano, Caserta



• Università
• degli Studi
della Campania
Luigi Vanvitelli

Cardiovascular Disease

Together, heart disease, stroke, and other vascular conditions contribute to:



> 850,000 lives lost each year¹



> 650,000 lives lost annually to heart disease¹




> \$350 billion spent annually towards costs and lost productivity from premature death each year¹



1 in 7 U.S. dollars spent on health care goes towards cardiovascular disease (CVD)²

1. VITRANI SS, ALONSO, BENJAMIN EJ, BITTENCOURT MS, ET AL. HEART DISEASE STATISTICS- 2020 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION. CIRCULATION. 2020;141:E1-E458. DOI: 10.1161/CIR.0000000000000757.
 2. VIRANI SS, ALONSO A, BENJAMIN EJ, BITTENCOURT MS, CALLAWAY CW, CARSON AP, ET AL. HEART DISEASE AND STROKE STATISTICS-2020 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION. CIRCULATION. 2020;141(9):E139-596. DOI: 10.1161/CIR.0000000000000757.

Where Do We Start??



Defining Adherence



“The extent to which a person’s **behavior** (taking medication, following a diet, or making healthy lifestyle changes) corresponds with **agreed**-upon recommendations from a health-care provider”

World Health Organization, 2003

Defining Medication Adherence



“The patient’s conformance with the provider’s recommendation with respect to **timing, dosage, and frequency** of medication-taking during the **prescribed length of time**”

Agency for Healthcare Research and Quality

Remember this...



“Drugs don’t work in patients who don’t take them.”

- C. Everett Koop

Medication Adherence Statistics



- Approximately 20 to 30% of prescriptions are never picked up from the pharmacy
- 50% of medications for chronic diseases are not taken as prescribed
- An estimated 10% of hospitalizations in older adults may be caused by medication non-adherence
- Up to \$300 billion of avoidable health care costs have been attributed to non-adherence in the US annually
- A retrospective claims-based study of 1,705 patients with diabetes and hyperlipidemia showed that adherence decreased all-cause medical costs by 15%

The Problem With Non-Adherence




- Clinical/Health Outcomes
 - Poor therapeutic outcomes
 - Further disease progression
 - Decreased quality of life
- Economic Outcomes
 - Increased costs to healthcare system
 - Increased hospitalization
 - Increased frequency of Emergency Department visits
 - Increased physician visits
 - Loss of productivity


Most Common Reasons for Non-Adherence



- Forgetfulness
- Concern about side effects
- High drug costs
- Perceived lack of efficacy or low need



How Can We Predict Adherence?



Asking About Adherence



- Most people forget sometimes. How often do you forget to take your medicine?
- When you feel better, do you sometimes stop taking medicine?
- When you feel worse, do you sometimes stop taking your medicine?

Types of "Objective" Data


Objective Recordings



Laboratory Values



Self-Management Training



Address Specific Barriers

- What might be specific barriers to adherence?
- A few patients will need true exposure treatment (refer to behavioral health) for phobias (needles, taking pills)
- Help patients set reminders if they are forgetful



But Doc...



*I hate taking pills.
It seems like every time I come
to the doctor I get MORE pills!*



- Acknowledge taking pills can be difficult.
- Re-focus on why the medicine is important.
- Brainstorm options: taking with food, consulting with pharmacy regarding possible decreases in quantity of pills.

Importance of treatment adherence in secondary prevention

Only **60%** of included patients were **good adherents***

The good adherence to CV medication led to:

- **20% reduction of CVD risk**
- **35% reduction of all-cause mortality**

9,1% of all the events are due to poor adherence in patients with prescribed cardiovascular medications.

Metanalysis of 44 prospective studies, comprising 1,978,919 non-overlapping participants with CVD: 135,627 CVD events, 94,126 cases of all-cause mortality.

*Good adherence: $\geq 80\%$ taking medication.

Study promoted by the ESC with almost 2.000.000 patients included





Patient-related barriers



Physician-related barriers



Health care system-related barriers

Voluntary

- Lack of understanding of current disease condition
- Difficulty accepting disease severity
- Previous negative experience to therapy
- Skeptical on recommended treatment efficacy
- Poor trust in the health care provider
- Cultural and ethnic beliefs

Involuntary


- Low level of health literacy or education

- Complex medication regimen
- Poor awareness about patient adherence
- Insufficient explanation to patients about their medical condition and medications (benefits, side effects, time needed for medication to work, etc)
- Multiple physicians providing varying and possibly conflicting details to the patients
- Specialty of prescriber
- Poor understanding between patient and physician


- The economics of health care systems restricts the time spent between the physician and the patient. This results in insufficient time to
 - Provide proper patient education (about their medical condition or medication)
 - Assess patient medication-taking behavior
 - Address patients' concerns
 - Offer encouragements and tips to improve adherence
- Cost of medication
- Insufficient clinical monitoring

Pill burden is one of the major factors associated with poor adherence

Compliance has been shown to decrease as pill burden increases



INCREASED ADHERENCE, WHILE INITIALLY INCREASING PHARMACEUTICAL SPENDING, REDUCES HOSPITALIZATIONS AND OVERALL HEALTHCARE COSTS IN THE LONG TERM




- Increase in pharmaceutical costs
- Savings on Global Health Costs


Key determinants of therapeutic adherence



The patient must be the protagonist of the therapeutic project



Key determinants of therapeutic adherence




THERAPEUTIC ADHERENCE

EUROASPIRE V




Cardiovascular prevention requires a modern preventive cardiology programme with appropriate adaptation to medical and cultural settings in each country. All patients with CHD, or any other form of atherosclerotic disease, should be guaranteed access to such a programme **delivered by interdisciplinary teams** of healthcare professionals – nurses, dieticians, physiotherapists or physical activity specialists, psychologists and physicians - **addressing all aspects** of lifestyle, blood pressure, lipids and glucose management, **and adherence** to cardio-protective medications, in order to reduce their risk of recurrent cardiovascular events, improve quality of life and prolong survival.

A simplified dosing regimen improves therapy persistence



Dezii CM. Manag Care. 2000;9 (suppl):S2-S6.


Poor adherence to antihypertensive treatment in the medium term (6 months) is associated with an increased risk of events compared with subjects taking at least 80% of prescribed antihypertensive medication



18.806

Newly diagnosed hypertensives, recently treated for hypertension, and initially free of cardiovascular disease

Effects of Persistence/Adherence with Antihypertensive Drug Therapy on the Reduction in HR of Coronary (n = 6665) and Cerebrovascular (n = 5351) Outcomes in 242,594 Patients



Heroes of secondary prevention: the «Fantastic Four»

Beta-blockers


Statins



ACE-I/ARBs

Antiplatelet
therapy

Current secondary prevention: the « **Fantastic Four** »



DURING AND AFTER COVID-19 PANDEMIC...

NEW THERAPEUTIC
NON-PHARMACOLOGICAL STRATEGIES?



TeleHealth as opportunity to improve ADHERENCE






V: Università
degli Studi
della Campania
Lang. Vanvitelli
Scuola di Medicina e Chirurgia
Dipartimento di Scienze Mediche Traslazionali

IX SIMPOSIO SCIENTIFICO

CardioUpdate

HYBRID EDITION

#CardioUpdate2021



Save
the
date!

30 Novembre - 1 Dicembre 2021

CASERTA, Grand Hotel Vanvitelli

Responsabile Scientifico: Prof. Paolo Calabrò

Segreteria Organizzativa:



Tel 081 402093 - congressi@defla.it - f



#CardioUpdate2021

30 Novembre

1 Dicembre

Caserta, Grand Hotel Vanvitelli

SAVE THE DATE



Grazie dell'attenzione...

paolo.calabro@unicampania.it

